Intérêt du génotypage de l’UGT1A1 dans le cadre du traitement des cancers digestifs par irinotécan-Reference-Cited by-同舟云学术

Intérêt du génotypage de l’UGT1A1 dans le cadre du traitement des cancers digestifs par irinotécan

Published:2014-06 Issue:6 Volume:101 Page:533-553
ISSN:0007-4551
Container-title:Bulletin du Cancer
language:fr
Short-container-title:Bulletin du Cancer

Author:

Boyer Jean-Christophe,Etienne-Grimaldi Marie-Christine,Thomas Fabienne,Quaranta Sylvie,Picard Nicolas,Loriot Marie-Anne,Poncet Delphine,Gagnieu Marie-Claude,Ged Cécile,Broly Franck,Le Morvan Valérie,Bouquié Régis,Gaub Marie-Pierre,Philibert Laurent,Ghiringhelli François,Le Guellec Chantal

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Reference53 articles.

1. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer;Fuchs;J Clin Oncol,2003

2. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan;Innocenti;J Clin Oncol,2004

3. FFCD 2014. http://www.snfge.org/content/4-cancer-colorectal-metastatique

4. Takimoto CH (Ed). The camptothecins. Cancer Chemotherapy and biotherapy. 2nd ed. Philadelphia: Lippincott and Wilkins, 1996: 21pp.

5. Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma;Yano;Cancer Sci,2008

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A study of the association between UGT1A1*28 variant allele of UGT1A1 gene and colonic phenotype of sporadic colorectal cancer;Digestive and Liver Disease;2019-04

2. Cannabis and anticancer drugs: societal usage and expected pharmacological interactions - a review;Fundamental & Clinical Pharmacology;2018-07-02

3. Pharmacogenetics of anti-cancer drugs: State of the art and implementation – recommendations of the French National Network of Pharmacogenetics;Therapies;2017-04

4. Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx);Therapies;2017-04

5. Pharmacogénétique des médicaments anticancéreux : état des connaissances et des pratiques – recommandations du Réseau national de pharmacogénétique (RNPGx);Therapies;2017-04